Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

3.60USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$3.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
295,780
52-wk High
$6.66
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

ZIOPHARM Oncology Q4 Loss Per Share $0.13
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - ZIOPHARM Oncology Inc ::ZIOPHARM ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.13.‍ZIOPHARM BELIEVES ITS CURRENT RESOURCES WILL BE SUFFICIENT TO FUND ITS CURRENTLY PLANNED OPERATIONS INTO Q4 OF 2018​.Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

Ziopharm Oncology Addresses Rumors And Stock Volatility, Affirms 2018 Guidance
Tuesday, 6 Feb 2018 08:55am EST 

Feb 6 (Reuters) - Ziopharm Oncology Inc ::ZIOPHARM ONCOLOGY ADDRESSES RUMORS AND STOCK VOLATILITY, AFFIRMS 2018 GUIDANCE.COMPANY REAFFIRMS ITS GUIDANCE FOR ALL ACTIVITIES IN 2018.ZIOPHARM HAS HAD NO DISCUSSIONS AND HAS NO PLANS TO UNDERTAKE AN UNDERWRITTEN STOCK OFFERING AT THIS TIME​.AS OF DEC. 31, 2017, CO HAD $70.9 MILLION OF CASH RESOURCES & $34.6 MILLION FROM PRE-PAYMENT FOR PROGRAMS TO BE CONDUCTED BY CO.CURRENT RESOURCES WILL BE SUFFICIENT TO FUND ITS CURRENTLY PLANNED OPERATIONS INTO Q4 OF 2018​.  Full Article

Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018
Tuesday, 9 Jan 2018 07:00am EST 

Jan 9 (Reuters) - Ziopharm Oncology Inc ::ZIOPHARM ONCOLOGY PROVIDES UPDATE ON STANDOUT TECHNOLOGIES DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ZIOPHARM ONCOLOGY - UPDATED GUIDANCE ON PLANNED PIVOTAL TRIAL TO EVALUATE CONTROLLED IL-12 AND ANNOUNCED THAT IT WILL INITIATE IN SECOND HALF OF 2018.  Full Article

Ziopharm Oncology reports third quarter financial results
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities.Q3 loss per share $0.13.Q3 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S.  Full Article

Ziopharm Oncology reports Q2 loss per share $0.13
Monday, 31 Jul 2017 04:05pm EDT 

July 31 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports second quarter 2017 financial results and provides update on recent activities.Q2 loss per share $0.13.Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S.Qtrly collaboration revenue $1.6 million versus $1.7 million.  Full Article

CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology
Monday, 22 May 2017 04:21pm EDT 

May 22 (Reuters) - Ziopharm Oncology Inc ::CVI Investments Inc reports a 6.8 percent passive stake in Ziopharm Oncology Inc as of May 11, 2017 - sec filing.  Full Article

ZIOPHARM Oncology says offering of 9.71 mln common shares priced at $5.15/shr
Friday, 12 May 2017 09:20am EDT 

May 12 (Reuters) - Ziopharm Oncology Inc :Ziopharm oncology announces pricing of $50 million follow-on offering of common stock.Says offering of 9.71 million common shares priced at $5.15per share.Says offering of 9.71 million common shares priced at $5.15per share.  Full Article

ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
Tuesday, 2 May 2017 07:00am EDT 

May 2 (Reuters) - ZIOPHARM Oncology Inc :Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia.Ziopharm oncology inc - investigator-initiated ind application to fda for a phase 1 trial infusing cd33-specific car(+) t therapy is now active.Ziopharm oncology inc - first patient to be enrolled in study expected to begin treatment in q3 of 2017..  Full Article

Ziopharm Oncology reports Q1 loss per share $0.15
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Ziopharm Oncology Inc :Ziopharm Oncology reports first quarter 2017 financial results and provides update on recent activities.Q1 loss per share $0.15.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Ziopharm -ended quarter with cash and cash equivalents of about $66.4 million, which it believes will be sufficient to fund currently planned activities through Q4.  Full Article

Ziopharm Q4 loss per share $0.11
Thursday, 16 Feb 2017 04:05pm EST 

Ziopharm Oncology Inc : Ziopharm reports fourth-quarter 2016 financial results and provides update on recent activities . Q4 loss per share $0.11 .Q4 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ziopharm Oncology Reports Q1 Loss Per Share $0.15

* ZIOPHARM ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE